Ultra-pure lyophilized peptide powders manufactured under strict cGMP protocols, designed for custom formulation, bio-equivalent trial development, and hospital pharmaceutical integration.
An in-depth evaluation of the French metabolic therapeutics sector, regulatory framework by ANSM, and how qualified CDMO manufacturing resolves structural shortages across the EU.
According to epidemiological studies monitored by the French National Institute of Health and Medical Research (INSERM) and Ligue contre l'Obésité, over 17% of the French adult population suffers from obesity, while more than 3.5 million individuals are managed for Type-2 Diabetes (T2D). The surging clinical adoption of GLP-1 receptor agonists (such as Semaglutide, Tirzepatide, and emerging Retatrutide) has overwhelmed domestic pharmacy inventory across key French metropolitan centers including Paris, Lyon, Marseille, and Lille.
The Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) enforces rigorous pharmacological standards regarding drug bio-equivalence, sterile filling validation, and endotoxin monitoring. For commercial entities, CROs, and generic formulators serving France, securing finished peptide products (FDF) with complete European Pharmacopoeia (Ph. Eur.) alignment, DMF filings, and strict batch-to-batch HPLC purity documentation is mandatory for overcoming regulatory entry barriers.
Due to global manufacturing bottlenecks of pre-filled pen delivery systems, French hospital pharmacies and pharmaceutical distributors routinely experience critical inventory gaps. As a primary global manufacturer and exporter of sterile lyophilized peptide vials, Gentolex bridges this deficit by offering scaled contract manufacturing (CMO/CDMO), FDF licensing-out, and secondary packaging solutions tailored for French bio-pharmaceutical partners. Our direct cold-chain supply pathways guarantee uninterrupted delivery into key logistics gateways like Paris-CDG and Lyon-Saint Exupéry under validated temperature-controlled conditions (+2°C to +8°C and -20°C deep-freeze).
Combining mega-scale chemical synthesis infrastructure with advanced solid-phase peptide technologies to lower unit costs without compromising international quality standards.
Our facilities leverage automated Microwave-Assisted Solid-Phase Peptide Synthesis (SPPS) alongside scalable Liquid-Phase Peptide Synthesis (LPPS). This hybrid approach prevents racemization, optimizes hydrophobic peptide sequences (like Tirzepatide and Retatrutide), and ensures full chain elongation fidelity.
Equipped with ISO Class 5 / Grade A cleanrooms, our sterile fill-finish operations feature custom freeze-drying (lyophilization) cycles. This yields pristine cake structure, ensures moisture content below 2.0%, and maximizes long-term peptide bio-activity shelf-life up to 36 months.
We provide global partners with complete analytical packages including Reverse-Phase HPLC chromatograms, Liquid Chromatography-Mass Spectrometry (LC-MS) structural confirmation, Residual Solvent testing (ICH Q3C), TFA counter-ion exchange reports, and Certificate of Analysis (CoA).
From early single-receptor agonists to revolutionary dual and triple receptor co-agonists driving the global metabolic healthcare revolution.
| Peptide Molecule | Target Receptors | Mean Purity (HPLC) | Primary Clinical Focus | Available Finished Vial Dosages |
|---|---|---|---|---|
| Semaglutide | GLP-1R (Mono-agonist) | ≥ 99.0% | T2D & Chronic Weight Management | 10mg, 15mg, 20mg, 30mg Vials |
| Tirzepatide | GLP-1R / GIPR (Dual agonist) | ≥ 99.2% | Dual Incretin Synergistic Metabolic Control | 10mg, 15mg, 20mg, 30mg, 60mg Vials |
| Retatrutide | GLP-1R / GIPR / GCGR (Triple agonist) | ≥ 99.0% | Triple Pathway Energy Expenditure & Fatty Liver | 10mg, 20mg, 30mg Vials |
| Liraglutide | GLP-1R (Short-acting mono) | ≥ 98.5% | Daily Glycemic Regulation & Weight Loss | 15mg Powder Vials |
Clinical data reveals that multi-receptor activation (such as Tirzepatide's GLP-1/GIP co-agonism and Retatrutide's triple GLP-1/GIP/Glucagon mechanism) yields significantly higher body mass reduction (exceeding 20-24% in clinical trials) compared to mono-GLP-1 therapeutics. Chinese CDMO facilities lead the world in scaling these complex 39-amino-acid and 39-amino-acid synthetic structures with specialized lipophilic fatty acyl side-chains.
While commercial autoinjectors face chronic plastic and mechanical delivery assembly shortages in Europe, high-purity sterile lyophilized vials represent a versatile, cost-effective alternative for clinical trials, compounding pharmacies, and institutional healthcare supply chains serving France and surrounding EU territories.
Explore our export-ready range of high-purity lyophilized peptide vials engineered for French pharmaceutical importers, distributors, and contract laboratories.
Complementary peptide APIs and active metabolic compounds engineered for customized pharmaceutical research and specialized B2B procurement.
Gentolex’s goal is to create opportunities connecting the world with better services and guaranteed products. Up to date, Gentolex Group has been serving customers from more than 10 countries, specially, representatives are established in Mexico and South Africa.
Our main services focus on supplying peptides APIs and Custom Peptides, FDF license out, Technical Support & Consultation, Product Line and Lab Setup, Sourcing & Supply Chain Solutions.
With an overall factory construction area of 250,000 square meters under international standard, Gentolex offers flexible, scalable, and cost-effective CDMO solutions for clients in France and worldwide.
An overall factory construction area of 250,000 square meters under international standard to offer flexible, scalable and cost-effective solutions.
Gentolex offers an extensive range of APIs and intermediates for development study and commercial application with cGMP standard. Documents and Certificates are supported worldwide.
Providing technical support & consultation, product line and laboratory setup, alongside custom peptide synthesis and scale-up validation.
For those clients who prefer to avoid the complexity of dealing with multiple points of contact, we provide extra customized procurement services with superior supply chain sources.
Global Compliance & Supply Chain Partners
Key information regarding ANSM compliance, cold-chain customs clearance into France, purity validation, and CDMO contract terms.
All GLP-1 finished products (Semaglutide, Tirzepatide, Retatrutide) are synthesized in automated cGMP-certified facilities. Every batch undergoes rigorous quality control under European Pharmacopoeia monographs, including HPLC purity verification (≥99.0%), LC-MS mass identity confirmation, bacterial endotoxin assay (<0.05 EU/mg), and heavy metal residue testing. Complete Certificate of Analysis (CoA) and DMF documentation support seamless regulatory review in France.
Our sterile vials utilize optimized freeze-drying cycles with protective matrix excipients (such as mannitol/trehalose) ensuring low residual moisture (<2.0%). Vials are sealed under inert nitrogen atmosphere in Type I borosilicate glass vials with fluoropolymer-coated chlorobutyl rubber stoppers, maintaining structural integrity across temperature fluctuations during air express transit into France.
Yes. We offer end-to-end FDF OEM/ODM contract manufacturing, including custom dosage configurations (e.g., 10mg, 15mg, 20mg, 30mg, 60mg per vial), custom flip-off cap color coding, multilingual French packaging compliance, and secondary cartoning with anti-counterfeiting serialization for European markets.
Standard inventory orders ship within 3 to 5 business days, while custom CMO batch runs take approximately 3 to 4 weeks. Shipments to France utilize validated cold-chain logistics (+2°C to +8°C or dry ice -20°C) with real-time USB/IoT temperature loggers to ensure zero thermal degradation upon arrival at Paris-CDG or regional distribution facilities.
You can initiate cooperation by contacting our international B2B business team via the direct inquiry button below or emailing our technical consulting specialists. We sign standard NDAs, provide initial sample batches for analytical evaluation, and outline tech-transfer milestones.
Stay informed with technical literature, peptide API developments, and industrial research breakthroughs from Gentolex Group.
Introduction to Selank Acetate API: Selank Acetate API is a synthetic heptapeptide active pharmaceutical ingredient composed of the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Developed through neuropharmacological research, Selank is a derivative of endogenous peptide structures...
View Details
Trusted Thymosin Beta-4 API Manufacturer and Global Peptide Supplier: As a professional Thymosin Beta-4 API manufacturer and supplier, we provide high-quality Thymosin Beta-4 peptide API solutions for biotechnology companies and research organizations...
View Details
Introduction BPC-157 API: BPC-157 API is a synthetic pentadecapeptide that has gained increasing attention in peptide research due to its biological activities related to tissue repair, gastrointestinal protection, and inflammatory regulation...
View Details
With continuous development in neuroscience, peptide technology, and life science research, neuroactive peptides have become an important area of scientific investigation. Semax, a synthetic peptide derived from ACTH fragment, attracts global attention...
View Details
SS-31 API, also known as Elamipretide, MTP-131, Bendavia, is a synthetic mitochondria-targeting tetrapeptide designed to bind cardiolipin in the inner mitochondrial membrane. By stabilizing mitochondrial structure, SS-31 supports cellular bioenergetics...
View DetailsContact our B2B export specialists for GLP-1 finished products, DMF documentation, and contract manufacturing serving France.
Send Inquiry NowGet in touch with our CDMO engineering team to request sample vials, chromatographic technical data sheets, or a competitive quote for Tirzepatide, Semaglutide, and Retatrutide finished dosage forms.
Send Inquiry Now
